Non-Hodgkin Lymphoma Therapeutics Market Analysis Report 2020: Radiant Insights, Inc Summary Radiant Insights, a leading business intelligence provider, has released its latest research report, "NonHodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options", which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to NonHodgkin Lymphoma (NHL). Click For Report Details @ http://www.radiantinsights.com/research/non-hodgkin-lymphomatherapeutics-in-major-developed-markets-to-2020-new-entrants-and-promising-pipeline-widentargeted-and-immunotherapeutic-treatment-options The value of the NHL market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a modest Compound Annual Growth Rate (CAGR) of 7.4%. The expected launch of promising drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera (rituximab), will be the key growth drivers. The launch of a premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase inhibitors including idelalisib and ibrutinib (which already gained FDA approval) are expected to have a significant impact on the market size. Additionally, the extension of indications of several already marketed drugs such as Revlimid as a maintenance therapy for DLBCL, Velcade as a front-line therapy for MCL and Adcetris as front-line therapy for CD30 T-cell lymphoma, will fuel the growth during the forecast period. The emerging treatment challenges in the current treatment landscape (which include, treatment of refractory/relapsed disease and increasing rituximab resistance) are expected to be addressed by the promising NHL pipeline. In spite of a slew of expected approvals the market is set to increase a modest pace due to the patent expiry of the gold-standard therapy during the forecast period.
Scope The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. It includes - A brief introduction to NHL, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms